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The Complexity of  
Diagnosing Melanoma
Ashfaq A. Marghoob1 and Alon Scope1
Recognizing that a cure lies in timely detection, dermatologists strive to diagnose 
malignant melanoma (MM) at the earliest possible stage. The desire to achieve 
this goal without injudiciously and unnecessarily excising many benign lesions has 
led to numerous techniques that assist clinicians in differentiating nevi from MM, 
including clinical mnemonics and algorithms, optical imaging instruments, and 
computer-assisted diagnostic systems. Most of these seemingly diverse methods 
rely on evaluating the in vivo morphology of lesions. In this issue, Guitera et al. 
compare dermoscopy with reflectance confocal microscopy (RCM) in an attempt 
to determine which imaging modality facilitates accurate diagnosis of melano-
cytic lesions using diagnostic parameters such as sensitivity and specificity.
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The study by Guitera et al. (2009, this 
issue) is an important step toward future 
use of RCM as a “bedside” diagnostic 
tool. At this juncture, we reflect on the 
framework of the clinical diagnosis of 
melanocytic lesions and where in vivo 
imaging tools fit into this framework. 
Although Guitera et al. have shown that 
RCM increased diagnostic accuracy 
over dermoscopy, such a comparison 
may be an oversimplification of what 
occurs in real life. Components of skin 
examination and diagnostic aids are not 
mutually exclusive; rather, they provide 
complementary information necessary 
for rendering a correct decision. For 
example, in the study by Guitera et al., 
eight MMs that were misdiagnosed via 
RCM were correctly diagnosed with 
dermoscopy. On the other hand, 12 
MMs that were incorrectly identified 
with dermoscopy were correctly diag-
nosed via RCM. When dermoscopy 
and RCM were used together, sensitiv-
ity was highest, with only three mela-
nomas incorrectly classified.
To judge whether an in vivo diag-
nostic technique is truly superior in 
terms of diagnostic accuracy, it is essen-
tial to account for the complexity of 
the clinical decision-making process. 
Components of the skin examination 
used in the evaluation of lesions include 
patient-derived anamnestic data, ana-
lytical reasoning, comparative recogni-
tion, differential recognition, and pattern 
analysis, which is also known as gestalt 
(see Figure 1; Gachon et al., 2005). This 
information can then be integrated with 
information obtained via diagnostic 
tools such as dermoscopy and RCM. In 
fact, experts “use multiple, combined 
strategies to solve clinical problems, 
suggesting a high degree of mental flex-
ibility and adaptability in clinical rea-
soning” (Norman, 2006). Experts’ ability 
to rapidly extract pertinent information 
from multiple sources has proven diffi-
cult for automated vision instruments to 
recreate. Thus, it is the evolving human 
cognitive process that allows clinicians 
to identify MM despite its varied clinical 
faces.
The ABCD mnemonic, introduced 
in 1985, represents an analytical meth-
od for the evaluation of MM and was 
probably the first method conveyed 
by experts to the dermatological com-
munity and later to the general pub-
lic. However, the ABCD method did 
not help to distinguish some dysplas-
tic nevi from MMs and failed to iden-
tify some MMs at an early stage (e.g., 
MMs with a small diameter). The intro-
duction of analytical algorithms that 
utilize dermoscopy—such as the ABCD 
method of dermoscopy, the seven-point 
checklist, and the Menzies method—
have improved discrimination but have 
not eliminated the challenge of clini-
cally distinguishing MMs from some 
nevi (Roesch et al., 2006).
In 1990, patient anamnestic data, 
which included both historical criteria 
(i.e., the presence of new or chang-
ing lesions) and lesion symptomology, 
were emphasized to help detect MM. 
Such patient-derived information was 
sensitive for MM identification and 
allowed the detection of an additional 
subset of MM that defies the ABCDs. 
Thus was born the Glasgow checklist. 
Similarly, “E,” for evolution, was subse-
quently added to the ABCD mnemonic. 
However, patient self-reporting has lim-
itations, and the need to further improve 
the detection of new and changing 
lesions brought about the introduc-
tion of baseline whole-body photogra-
phy and short-term dermoscopic mole 
monitoring in clinical practice—both of 
|RCM increases specificity above dermoscopic 
assessment alone.
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which rely on our comparative image-
recognition process. The underlying 
premise of change as a sensitive sign for 
MM diagnosis is that MMs tend to be 
more biologically dynamic than nevi, 
even over as little as a 3-month period 
of follow-up (Altamura et al., 2008).
Another milestone in MM detection 
was the acknowledgment of the impor-
tance of differential recognition pro-
cesses. In 1998, Grob and Bonerandi 
(Grob et al., 1998) described the “ugly 
duckling” sign for MM detection. 
This clinical sign emphasizes that it is 
imperative that we not only evaluate 
the morphology of the lesion in ques-
tion but also compare it with the sur-
rounding moles. Outlier lesions that 
look different from surrounding nevi 
tend to attract our attention, and some 
of these lesions do indeed prove to be 
MMs (Scope et al., 2008). Although the 
ugly-duckling sign is usually applied 
to unaided clinical evaluation, it has 
the potential to be utilized in dermo-
scopic evaluation because individuals 
also tend to harbor a limited number 
of dermoscopic patterns in their nevi, 
a concept known as “moles breed 
true” (Scope et al., 2006). Thus, the 
ugly-duckling sign and moles-breed-
true concept are two sides of the same 
coin, namely, the differential recogni-
tion process of isolating lesions that 
are morphologically different from 
the common denominator. This con-
cept can be broadened over the afore-
mentioned parameters of change and 
symptoms; although change in nevi 
is not uncommon, MMs will change 
differently than nevi and may pro-
duce unique symptoms and signs that 
prompt MMs to be singled out (Banky 
et al., 2005).
No one has been able to peer into 
experts’ brains to determine exactly 
how they analyze pigmented lesions. 
However, some insights are becom-
ing apparent (Montgomery, 2006). We 
believe the following may constitute an 
overall scheme (summarized in Table 1). 
In patients with numerous moles, we 
try to identify suspicious lesions by 
patient history of change or symptoms, 
comparison with baseline images, and 
the search for an outlier lesion that 
looks different from the neighboring 
moles (i.e., the ugly-duckling sign). 
Once a suspect lesion has been identi-
fied, we use naked-eye clinical exami-
nation; if more information is needed, 
we may employ a magnifying lens or 
a dermatoscope. If the overall appear-
ance of the lesion is recognized as a 
benign pattern, we move on. On the 
other hand, if the overall pattern fits 
the gestalt of a clear-cut MM, we opt 
for surgical removal. In cases where the 
pattern cannot be easily categorized as 
either benign or malignant, we may use 
analytical criteria (e.g., search for mela-
noma-specific dermoscopic structures). 
Figure 1. The final decision of whether to biopsy a lesion is not simple. The main components of this 
cognitive process involve differential recognition (e.g., the “Ugly Duckling sign”), analytical recognition 
(e.g., the “Little Red Riding Hood sign,” Mascaro et al., 1998), pattern recognition (e.g., the “Beauty and 
the Beast sign,” Marghoob et al., 2007), and comparative recognition. All of these processes occur on the 
clinical level, but they can be augmented by tools such as dermoscopy and RCM. Admittedly, there is 
probably more complexity to decision making than depicted. Personality attributes such as experience and 
contextual factors such as time pressure may influence the process. Finally, there are cognitive processes not 
yet scientifically identified but generically referred to as “gut feelings.” ABCD, asymmetry, borders, color, 
diameter—criteria for assessment. RCM, reflectance confocal microscopy.
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Comparative recognition
(e.g., comparison to total body
photography, short-term dermoscopic
mole monitoring)
Differential recognition
(e.g., clinical or dermoscopic
outlier lesions)
Analytical evaluation
(e.g., clinical ABCD,
dermoscopic criteria, RCM
criteria)
table 1. General scheme of clinical approach to pigmented lesions
Level of diagnosis relevant signs, mnemonics, and algorithms comments
Level 1, “macro”:  
whole-body screening
Patient history (Glasgow seven-point checklist)
Context: patient age and anatomical location of lesion
“Ugly Duckling” vs. “moles breed true”: differential recognition
WBP: comparative recognition
Saccade (scanning) vision is active
Main determinant of sensitivity
Level 2, “micro”:  
individual lesion assessment
Analytical criteria (ABCD mnemonic, ABCD rule of dermoscopy, 
Menzies method, seven-point checklist of dermoscopy)
Pattern analysis at the clinical and dermoscopic levels
RCM
Short-term mole monitoring
Saccade vision is suppressed
Focused vision (light focused on fovea,  
allowing for sharp color vision) is active
Main determinant of specificity
ABCD, asymmetry, borders, color, diameter—criteria for assessment; WBP, whole-body photography; RCM, reflectance confocal microscopy.
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However, if we are still unable to find 
conclusive criteria for differentiating 
the lesion as benign or malignant, we 
may opt to gather more information. 
RCM may provide additional diagnos-
tic information because of the ability 
to view tissue with cellular resolution 
with thin optical sections from the level 
of the stratum corneum to the papillary 
dermis. Based on the integration of all 
the aforementioned examination meth-
ods and diagnostic tools, we decide 
whether the lesion must be surgically 
removed or followed using techniques 
such as short-term mole monitoring to 
further assess its biological nature.
It is clear from the study by Guitera 
et al. (2009, this issue) that RCM sig-
nificantly increases specificity beyond 
that of dermoscopic assessment 
because it adds new features that help 
to correctly diagnose many dermo-
scopically equivocal lesions as nevi, 
including those that are pink or lightly 
pigmented. Such an increase in speci-
ficity should ultimately translate into 
a decrease in unnecessary surgical 
removal of many nevi. However, the 
ultimate goal is not to overlook MM 
(i.e., the goal is to increase sensitivity). 
Has this been achieved in this study? 
As mentioned above, dermoscopy and 
RCM together enabled the researchers 
to correctly identify more MMs, albeit 
not 100% of MMs in the study. Yet one 
may argue that the true sensitivity for 
the diagnosis of lesions in this study, or 
in any study based on excised lesions, 
is actually 100%, because all MMs 
in this study were actually removed 
by the clinicians, probably based on 
the complex clinical decision-mak-
ing process rather than dermoscopy, 
RCM, or both. In fact, no study today 
tries to measure the real-life sensitiv-
ity for MM detection because that 
would require either removing all skin 
lesions for histopathological analysis, 
including those that appear clinically 
banal, or following patients for many 
years to ensure that absolutely no 
MMs were missed.
Even after a complete skin exami-
nation in a systematic manner, some 
MMs may appear banal and may be 
simply overlooked, whereas others 
may initially catch our attention but 
be erroneously dismissed as benign. 
The various components of the exami-
nation (e.g., patient history, assessing 
for outlier lesions) and diagnostic aids 
(such as dermoscopy and RCM) may 
be viewed as complementary “filters” 
that help catch MM. Another safe-
guard against “missed” MM is periodic 
patient examinations. These examina-
tions provide an additional opportu-
nity for the patient to pass through our 
filters, allowing us to monitor changes 
that may have developed in the MM 
during the elapsed interval.
MM detection is complex. The search 
for more robust methods to diagnose 
it has helped us recognize the many 
faces of this malignancy, some of 
which would probably have escaped 
detection were it not for our increased 
knowledge. For example, light-colored 
MMs are often difficult to diagnose. 
However, based on the study by Guitera 
et al., RCM may prove to be beneficial 
in correctly identifying these lesions. 
As stated by the philosopher Goethe, 
“The eyes see only that which the mind 
is prepared to comprehend.” From the 
beginning of time, MMs have had col-
ors, structures, and patterns for all to 
see; however, “some see but do not 
comprehend” (Davis, 1978). The pursuit 
of the ever-elusive “perfect” method to 
detect MM continues to enrich our abil-
ity to recognize many MMs that would 
have been missed in the past. There is 
a subset of MMs that can be diagnosed 
only by patient history, some that can 
be diagnosed instantly “from the exami-
nation room doorway” by gestalt, and 
others that require a combination of 
analytical, differential, and comparative 
recognition. This process is enhanced 
by instruments such as the magnify-
ing lens or dermoscope. Now, with 
RCM, we have a new tool to add to our 
arma mentarium.
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